Opinion|Videos|March 11, 2025
Sequencing Multiple Lines of Therapy in Metastatic RCC
Author(s)Pedro Barata, MD, MSc, FACP
An expert discusses using sequence therapies based on disease progression, patient factors, and resistance mechanisms. After a first-line tyrosine kinase inhibitor plus immune checkpoint inhibitor (TKI + ICI) regimen, preferred subsequent-line options include alternative TKIs, chemotherapy, or combination strategies, tailored to patient response and tolerability.
Episodes in this series
Video content above is prompted by the following:
- How are you sequencing these agents through multiple lines of therapy?
- Thinking beyond the patient case just reviewed, please discuss your preferred subsequent line after a first-line TKI + ICI regimen.
- Would you have followed the sequence of therapies used for the patient described in this case?
Related Content
Advertisement
